Rana Rashmi, Devi Shamjetsabam Nandibala, Bhardwaj Amit Kumar, Yashavarddhan M H, Bohra Deepika, Ganguly Nirmal Kumar
Department of Biotechnology and Research, Sir Ganga Ram Hospital, New Delhi 110060, India.
Department of Biotechnology and Research, Sir Ganga Ram Hospital, New Delhi 110060, India.
Biomed Pharmacother. 2025 Jan;182:117754. doi: 10.1016/j.biopha.2024.117754. Epub 2024 Dec 27.
Exosomes, minute vesicles originating from diverse cell types, exhibit considerable potential as carriers for drug delivery in glioma therapy. These naturally occurring nanocarriers facilitate the transfer of proteins, RNAs, and lipids between cells, offering advantages such as biocompatibility, efficient cellular absorption, and the capability to traverse the blood-brain barrier (BBB). In the realm of cancer, particularly gliomas, exosomes play pivotal roles in modulating tumor growth, regulating immunity, and combating drug resistance. Moreover, exosomes serve as valuable biomarkers for diagnosing diseases and assessing prognosis. This review aims to elucidate the therapeutic and diagnostic promise of exosomes in glioma treatment, highlighting the innovative advances in exosome engineering that enable precise drug loading and targeting. By circumventing challenges associated with current glioma treatments, exosome-mediated drug delivery strategies can enhance the efficacy of chemotherapy drugs like temozolomide and overcome drug resistance mechanisms. This review underscores the multifaceted roles of exosomes in glioma pathogenesis and therapy, underscoring their potential as natural nanocarriers for targeted therapy and heralding a new era of hope for glioma treatment.
外泌体是源自多种细胞类型的微小囊泡,在神经胶质瘤治疗中作为药物递送载体具有巨大潜力。这些天然存在的纳米载体促进细胞间蛋白质、RNA和脂质的传递,具有生物相容性、高效细胞吸收以及穿越血脑屏障(BBB)的能力等优势。在癌症领域,特别是神经胶质瘤中,外泌体在调节肿瘤生长、调节免疫和对抗耐药性方面发挥着关键作用。此外,外泌体可作为诊断疾病和评估预后的重要生物标志物。本综述旨在阐明外泌体在神经胶质瘤治疗中的治疗和诊断前景,突出外泌体工程的创新进展,这些进展能够实现精确的药物装载和靶向。通过规避当前神经胶质瘤治疗相关的挑战,外泌体介导的药物递送策略可以提高替莫唑胺等化疗药物的疗效,并克服耐药机制。本综述强调了外泌体在神经胶质瘤发病机制和治疗中的多方面作用,突显了它们作为靶向治疗天然纳米载体的潜力,并预示着神经胶质瘤治疗充满希望的新时代。
Biomed Pharmacother. 2025-1
J Nanobiotechnology. 2025-5-3
Int J Mol Sci. 2024-11-21
J Nanobiotechnology. 2024-6-18
J Drug Target. 2021-11
Int J Nanomedicine. 2020-10-28
Colloids Surf B Biointerfaces. 2025-1
Front Pharmacol. 2025-8-21
Front Bioeng Biotechnol. 2025-7-23
Int J Mol Sci. 2025-7-15
Int J Mol Sci. 2025-6-18
IBRO Neurosci Rep. 2025-2-5